Source:http://linkedlifedata.com/resource/pubmed/id/14726893
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-1-16
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0190-9622
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
301-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14726893-Arthritis, Rheumatoid,
pubmed-meshheading:14726893-Combined Modality Therapy,
pubmed-meshheading:14726893-Dermatologic Agents,
pubmed-meshheading:14726893-Humans,
pubmed-meshheading:14726893-Methotrexate,
pubmed-meshheading:14726893-Practice Guidelines as Topic,
pubmed-meshheading:14726893-Psoriasis
|
pubmed:year |
2004
|
pubmed:articleTitle |
Methotrexate and psoriasis in the era of new biologic agents.
|
pubmed:affiliation |
Baylor University Medical Center, Dallas, Texas 75230, USA.
|
pubmed:publicationType |
Journal Article,
Review
|